BR112012015561A8 - anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais - Google Patents
anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionaisInfo
- Publication number
- BR112012015561A8 BR112012015561A8 BR112012015561A BR112012015561A BR112012015561A8 BR 112012015561 A8 BR112012015561 A8 BR 112012015561A8 BR 112012015561 A BR112012015561 A BR 112012015561A BR 112012015561 A BR112012015561 A BR 112012015561A BR 112012015561 A8 BR112012015561 A8 BR 112012015561A8
- Authority
- BR
- Brazil
- Prior art keywords
- receptors
- antibodies
- directed against
- antibodies directed
- against non
- Prior art date
Links
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- 238000011319 anticancer therapy Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
anticorpos dirigidos contra receptores p27x7 oligoméricos não funcionais. a invenção se refere a receptores purinérgicos, a anticorpos e seus fragmentos relacionados para ligação aos referidos receptores, à produção dos referidos anticorpos e fragmentos e ao uso dos referidos anticorpos e fragmentos para detecçã de câncer e terapia anticâncer. em partcular, os anticorpos descritos sse ligam especificamente aos receptores p2x7 não funcionais expressos por células vivas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009906286A AU2009906286A0 (en) | 2009-12-24 | Anti P2X7 receptor antibodies and fragments thereof | |
PCT/AU2010/001741 WO2011075789A1 (en) | 2009-12-24 | 2010-12-23 | Antibodies to non-functional oligomeric p2x7 receptors |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112012015561A2 BR112012015561A2 (pt) | 2017-01-31 |
BR112012015561A8 true BR112012015561A8 (pt) | 2019-10-01 |
BR112012015561B1 BR112012015561B1 (pt) | 2019-11-12 |
Family
ID=44194835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012015561-0A BR112012015561B1 (pt) | 2009-12-24 | 2010-12-23 | anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais |
Country Status (9)
Country | Link |
---|---|
US (2) | US8835609B2 (pt) |
EP (2) | EP2516470B1 (pt) |
JP (1) | JP5992831B2 (pt) |
CN (1) | CN102762595B (pt) |
AU (1) | AU2010336032C1 (pt) |
BR (1) | BR112012015561B1 (pt) |
CA (1) | CA2784345C (pt) |
ES (2) | ES2667003T3 (pt) |
WO (1) | WO2011075789A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2434490C (en) | 2001-01-17 | 2014-06-03 | Intreat Pty Limited | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
EP2201026B1 (en) | 2007-09-14 | 2017-01-04 | Biosceptre (Aust) Pty Ltd | Novel p2x7 epitopes |
US8293491B2 (en) | 2007-09-14 | 2012-10-23 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
KR101701300B1 (ko) | 2008-07-04 | 2017-02-01 | 바이오셉터 (어스트) 피티와이 엘티디 | 항p2x7 펩티드 및 에피토프 |
JP5936067B2 (ja) | 2009-08-20 | 2016-06-15 | バイオセプター・(オーストラリア)・ピーティーワイ・リミテッド | 抗p2x7受容体抗体およびその断片 |
ES2667003T3 (es) | 2009-12-24 | 2018-05-09 | Biosceptre (Aust) Pty Ltd | Anticuerpos para receptores P2X7 oligoméricos no funcionales |
US9562094B2 (en) | 2010-09-10 | 2017-02-07 | Biosceptre (Aust) Pty Ltd | Companion animal treatments |
BR112013033974A2 (pt) | 2011-07-01 | 2017-02-14 | Biosceptre Int Ltd | terapia de combinação |
WO2014003137A1 (ja) * | 2012-06-27 | 2014-01-03 | 旭化成メディカル株式会社 | 高アフィニティー抗体、及びその製造方法 |
JP6790062B2 (ja) * | 2015-04-02 | 2020-11-25 | バイオセプター・(ユーケー)・リミテッド | 疼痛治療 |
EP3816294A1 (en) * | 2015-09-11 | 2021-05-05 | Biosceptre (UK) Limited | Chimeric antigen receptors and uses thereof |
US11260131B2 (en) | 2016-10-21 | 2022-03-01 | Biosceptre (Aust) Pty Ltd | Cytotoxic particles for targeting P2X7 receptor |
JP2021518748A (ja) * | 2018-02-23 | 2021-08-05 | アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc | カルシトニン遺伝子関連ペプチド(cgrp)アンタゴニスト抗体 |
WO2019229296A1 (en) | 2018-05-29 | 2019-12-05 | Teknologian Tutkimuskeskus Vtt Oy | Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment |
CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
MX2021015593A (es) * | 2019-07-26 | 2022-04-11 | Biosceptre Aust Pty Ltd | Métodos de tratamiento. |
EP4304610A1 (en) * | 2021-03-11 | 2024-01-17 | Biosceptre (Aust) Pty Ltd | Novel cell therapy system |
CN117881421A (zh) * | 2021-09-01 | 2024-04-12 | 生物权威(澳大利亚)有限责任公司 | 用于刺激免疫活性的方法和组合物 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE920765A1 (en) | 1991-03-12 | 1992-09-23 | Scripps Research Inst | Cell surface receptors homologous to coagulation factors v¹and viii |
JPH10501122A (ja) | 1994-05-27 | 1998-02-03 | グラクソ、グループ、リミテッド | P▲下2x▼レセプター(プリノセプターファミリー) |
CA2228999A1 (en) | 1995-08-09 | 1997-02-20 | Institut National De La Sante Et De La Recherche Medicale | Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis |
EP0907729A1 (en) | 1996-04-30 | 1999-04-14 | Smithkline Beecham Plc | HUMAN P2x4 RECEPTOR SPLICE-VARIANTS |
US6303338B1 (en) | 1996-08-16 | 2001-10-16 | Human Genome Sciences, Inc. | Pancreas-derived plasminogen activator inhibitor |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
US6133434A (en) | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
ES2629442T3 (es) | 1998-06-01 | 2017-08-09 | Agensys, Inc. | Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos |
DE19829473C2 (de) | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
EP1157038A4 (en) | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17) |
AUPP991199A0 (en) | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
WO2001030964A2 (en) | 1999-10-22 | 2001-05-03 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
AUPR201500A0 (en) | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
CA2434490C (en) | 2001-01-17 | 2014-06-03 | Intreat Pty Limited | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
CN100497386C (zh) | 2001-09-03 | 2009-06-10 | 因特里特有限公司 | 非功能性p2x7受体的抗体及其应用 |
ATE371738T1 (de) | 2003-04-17 | 2007-09-15 | Affectis Pharmaceuticals Ag | Mittel und verfahren zur diagnose und behandlung affektiver störungen |
CA2607541A1 (en) | 2005-05-05 | 2006-12-28 | Medicure International Inc. | Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds |
US7767789B2 (en) | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
EP1929305A2 (en) | 2005-08-31 | 2008-06-11 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
EP2082032A4 (en) | 2006-10-10 | 2010-06-30 | Biosceptre Int Ltd | ANTIBODIES AGAINST NON-FUNCTIONAL P2X7 RECEPTOR PRODUCING HYBRIDOMES |
US20100036101A1 (en) | 2006-10-10 | 2010-02-11 | Angus Gidley-Baird | Antibodies against non functional p2x7 receptor |
US8293491B2 (en) | 2007-09-14 | 2012-10-23 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
EP2201026B1 (en) * | 2007-09-14 | 2017-01-04 | Biosceptre (Aust) Pty Ltd | Novel p2x7 epitopes |
KR101701300B1 (ko) | 2008-07-04 | 2017-02-01 | 바이오셉터 (어스트) 피티와이 엘티디 | 항p2x7 펩티드 및 에피토프 |
JP5936067B2 (ja) | 2009-08-20 | 2016-06-15 | バイオセプター・(オーストラリア)・ピーティーワイ・リミテッド | 抗p2x7受容体抗体およびその断片 |
ES2667003T3 (es) | 2009-12-24 | 2018-05-09 | Biosceptre (Aust) Pty Ltd | Anticuerpos para receptores P2X7 oligoméricos no funcionales |
WO2011131472A1 (en) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
US9562094B2 (en) | 2010-09-10 | 2017-02-07 | Biosceptre (Aust) Pty Ltd | Companion animal treatments |
BR112013033974A2 (pt) | 2011-07-01 | 2017-02-14 | Biosceptre Int Ltd | terapia de combinação |
-
2010
- 2010-12-23 ES ES10838429.8T patent/ES2667003T3/es active Active
- 2010-12-23 JP JP2012545019A patent/JP5992831B2/ja active Active
- 2010-12-23 US US13/518,382 patent/US8835609B2/en active Active
- 2010-12-23 ES ES17209838T patent/ES2732021T3/es active Active
- 2010-12-23 BR BR112012015561-0A patent/BR112012015561B1/pt active IP Right Grant
- 2010-12-23 CN CN201080063868.6A patent/CN102762595B/zh active Active
- 2010-12-23 WO PCT/AU2010/001741 patent/WO2011075789A1/en active Application Filing
- 2010-12-23 EP EP10838429.8A patent/EP2516470B1/en active Active
- 2010-12-23 EP EP17209838.6A patent/EP3321285B1/en active Active
- 2010-12-23 AU AU2010336032A patent/AU2010336032C1/en active Active
- 2010-12-23 CA CA2784345A patent/CA2784345C/en active Active
-
2014
- 2014-08-11 US US14/456,898 patent/US9428587B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2784345A1 (en) | 2011-06-30 |
EP2516470A1 (en) | 2012-10-31 |
ES2667003T3 (es) | 2018-05-09 |
CA2784345C (en) | 2018-11-13 |
US20150218283A1 (en) | 2015-08-06 |
US20120329076A1 (en) | 2012-12-27 |
AU2010336032C1 (en) | 2016-04-21 |
AU2010336032A1 (en) | 2012-07-12 |
ES2732021T3 (es) | 2019-11-20 |
US9428587B2 (en) | 2016-08-30 |
BR112012015561B1 (pt) | 2019-11-12 |
EP3321285A1 (en) | 2018-05-16 |
US8835609B2 (en) | 2014-09-16 |
CN102762595B (zh) | 2016-03-02 |
AU2010336032B2 (en) | 2016-01-28 |
BR112012015561A2 (pt) | 2017-01-31 |
JP5992831B2 (ja) | 2016-09-14 |
CN102762595A (zh) | 2012-10-31 |
EP2516470A4 (en) | 2013-05-22 |
JP2013515013A (ja) | 2013-05-02 |
EP2516470B1 (en) | 2018-02-07 |
EP3321285B1 (en) | 2019-04-24 |
WO2011075789A1 (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012015561A8 (pt) | anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais | |
CL2021000353A1 (es) | Anticuerpo o fragmento de anticuerpo del mismo que comprende una región de unión que se une a un supresor del dominio vista, composición que lo comprende, su uso para tratar o prevenir el cáncer, ácido nucleico aislado, vector de expresión, célula hospedadora, método para producir dicho anticuerpo o fragmento del mismo, y artículo de fabricación (divisional de solicitud n° 01646-2016) | |
CY1119154T1 (el) | Anti-vla-4 αντισωματα | |
CY1121637T1 (el) | Αντι-dkk-1 αντισωματα | |
TN2015000396A1 (en) | Antibody drug conjugates | |
CL2013000459A1 (es) | Anticuerpo aislado o fragmento que se enlaza a un estado inactivo de un receptor her; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar cancer. | |
MX344009B (es) | Conjugados de amatoxinas con enlaces mejorados. | |
BR112018006360A2 (pt) | anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso | |
DK2776466T3 (da) | Albuminbindende antistoffer og bindingsfragmenter deraf | |
ECSP088750A (es) | Métodos y composiciones para antagonismo de rage | |
BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
BR112013017080A2 (pt) | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente | |
FR2924894B1 (fr) | Pieces en materiau composite electro-structural. | |
DK2885639T3 (da) | Kompleksspecifikke antistoffer og antistoffragmenter og deres anvendelse | |
AR088512A1 (es) | Anticuerpos dirigidos contra el tnf | |
PH12016500275B1 (en) | Antibodies | |
BR112013033171A2 (pt) | composição. método para preparar uma composição, fibra ou material fibroso e elemento de filtro | |
NI200900189A (es) | Anticuerpos contra la il-25 | |
WO2014163714A3 (en) | Antibody drug conjugates | |
BRPI1012875B8 (pt) | composições farmacêuticas sólidas e processos para sua produção | |
CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. | |
PT2609119T (pt) | Proteínas de ligação ao antigénio de polissacáridos quitinosos | |
AR095268A1 (es) | ANTICUERPOS HUMANOS QUE SE UNEN AL FACTOR a DE LA NECROSIS (TNF-a) HUMANO Y MÉTODOS PARA PREPARARLOS | |
CL2013002006A1 (es) | Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto. | |
ATE526338T1 (de) | Alkyl- und/oder alkenylether von alkyl- und/oder alkenyl(poly)glycosiden und ihre verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2010, OBSERVADAS AS CONDICOES LEGAIS |